ImmuPharma plc (LON:IMM – Get Free Report) shares were up 13.4% on Wednesday . The company traded as high as GBX 10.80 and last traded at GBX 10.50. Approximately 7,067,300 shares were traded during trading, a decline of 12% from the average daily volume of 8,072,208 shares. The stock had previously closed at GBX 9.26.
ImmuPharma Stock Performance
The company has a market cap of £52.79 million, a P/E ratio of -11.80 and a beta of 1.53. The firm’s fifty day moving average is GBX 10.98 and its two-hundred day moving average is GBX 5.43.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Carving Up Profits: 3 Food Stocks on the Thanksgiving Table
- What is a Dividend King?
- C3.ai’s Reset: Why New Leadership Could Spark a Turnaround
- What is the Euro STOXX 50 Index?
- CleanSpark Secures $1.15B, Stock Drops—Here’s Why It’s an Opportunity
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
